Cogentis Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Cogentis Therapeutics, Inc. - overview
Established
2015
Location
Baltimore, MD, US
Primary Industry
Biotechnology
About
Based in Maryland, US, and founded in 2015 by Kent Werner (CEO), Cogentis Therapeutics, Inc. operates as an early-stage biotechnology company focused on developing disease-modifying therapeutics for various neurodegenerative diseases. In October 2020, Cogentis Therapeutics raised Non-Equity from MassChallenge. The firm discovers and commercializes treatments aimed at preventing neurodegeneration and restoring brain function, specially Alzheimer's disease, frontotemporal dementia, Parkinson's disease, and amyotrophic lateral sclerosis (ALS).
Cogentis also offers a peptide-based compound, CT-526, which helps in the detection and prevention of frontotemporal dementia, progressive supranuclear palsy, and more.
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Diagnostic, Medical & Imaging Laboratories, Diagnostic Equipment
Website
www.cogentistherapeutics.com/
Verticals
HealthTech
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.